February, 2017 - "Wellcome Trust gives Polyphor CHF 2.3 Million form antibiotic development" - Drug Target Review

February 9, 2017 - Polyphor receives CHF 2.3 Million Award from Wellcome Trust

December 12, 2016 - Polyphor achieves milestone in Taisho collaboration

December 7, 2016 - Polyphor achieves milestone and extends R&D collaboration

October 18, 2016 - Giacomo Di Nepi Appointed New CEO of Polyphor

August 10, 2016 - Polyphor and Gilead establish R&D macrocycle drug discovery collaboration.

June 06, 2016 - Polyphor successfully completes clinical Phase I study with POL6014 targeting life threatening lung diseases including cystic fibrosis.

March 23, 2016 - Polyphor announces $3 Million Award from Cystic Fibrosis Foundation Therapeutics to advance the clinical development of POL6014.

December 22, 2015 - Polyphor and Boehringer Ingelheim extend macrocyle R&D collaboration.

December 1, 2015 – Polyphor announces extension of R&D collaboration.

September 17, 2015 – Polyphor and Taisho enter into research collaboration on novel drug candidates.

September 15, 2015 – Polyphor is nominated for the Prix SVC Nordschweiz.

September 1, 2015 – Polyphor extends clinical development portfolio by advancing its inhaled elastase inhibitor POL6014 for lung diseases to Phase I.

March 17, 2015  Polyphor appoints new CEO and strengthens executive management team.

January 9, 2015 Polyphor develops the elastase inhibitor POL6014 for rare lung diseases using PARI Pharma's eFlow® Technology inhalation device.

November 12, 2014 Polyphor's lead antibiotic POL7080 receives Qualified Infectious Disease Product (QIDP) designation from the FDA.

November 4, 2013 – Polyphor and Roche join efforts to combat multidrug-resistant bacterial infections. German translationFrench translation.

July 31, 2013 – Polyphor achieves first milestone in MacroFinder® collaboration with Boehringer Ingelheim.

June 11, 2013 – Polyphor attracts senior Pharma professionals to strengthen its Board of Directors.

March 4, 2013  Polyphor announces successful Phase I results for its Pseudomonas selective antibiotic POL7080.

June 12, 2012 – Polyphor and Boehringer Ingelheim announce MacroFinder® collaboration.

July 27, 2011 - Polyphor and Axxam announce EU funded R&D collaboration for the treatment of Type-2 Diabetes.

May 6, 2010 - Polyphor and Novartis announce PEMfinder® collaboration.

April 12, 2010 - Polyphor and Axxam SpA announce ion channel collaboration

February 19, 2010 - Polyphor discovers a new class of antibiotics with a novel mode of action. New weapon in the fight against multi-drug resistant bacteria published in “Science” (click here for German version).

Polyphor Ltd
Hegenheimermattweg 125
CH-4123 Allschwil
Switzerland
Tel. +41 61 567 16 00
Fax +41 61 567 16 01
info@polyphor.com

Last modified:   14.02.2017